Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 948 2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

Oldshoe Jun. 1 at 4:57 PM

$KAPA What I expect. 1- The next few weeks continue to be low volume. 2- Roughly around same time as s/h voting materials are issued (estimate mid-June), expecting another PR about 'partnership' with Celyn/CL-273 (mild catalyst, sustains mild mkt interest). 3- Within a week before (or during) annual meeting, news about NSCLC phase 1 safety & interim efficacy (moderate catalyst, some price rise to form new level). 4- Price likely to mostly sustain at the new level through expected r/s occurring July/Aug - that time frame coincides with start of likely run-up to p2 prostate cancer trial efficacy update that the company has announced will be released Q3 (significant catalyst good or bad; note that good safety & efficacy was indicated in p1). 5- Final trial data for phase 2 prostate cancer trial expected to be released 1Q2027 (mid/late March release most likely). All that is ONLY my opinion at this time - I could be quite wrong - not financial advice in any way.

1 · Reply

TraderBuckNKY Jun. 1 at 3:45 PM

$KAPA ...hopefully the Kool-Aid is completely dried up and we can all sell at a loss and move on...other sectors are screaming while we have continued to sip and sigh and hope. "management" has either horribly mis-managed or; lied, deceived, fabricated and concocted a twisted tale of deception and a flossing of the US retail investor. We've seen this story play out before many times...and, is it possible that ICE/certain government agencies are challenging the Work Visas of several key management personnel... ?

0 · Reply

TB85 May. 29 at 5:21 PM

$KAPA I dont remeber dates and such! But, is there any risk of an RS in kapa any time soon?? I mean, ive been watching it from the bench, before i got in again. And the lack of updates and any kind of news, seems still to be a major problem to "stimulate" the sp.👀

1 · Reply

TraderBuckNKY May. 29 at 2:45 PM

$KAPA

0 · Reply

Oldshoe May. 27 at 4:30 PM

$KAPA

0 · Reply

Turkialharbi70 May. 26 at 1:14 PM

$KAPA

0 · Reply

uptrend2025 May. 22 at 2:19 PM

$KAPA Data and Partnership News next week?

0 · Reply

ezcheezie May. 21 at 8:25 PM

$KAPA Interesting my comment got deleted for some reason.

1 · Reply

uptrend2025 May. 21 at 8:02 PM

$KAPA 🚀 🚀

1 · Reply

Oldshoe May. 21 at 7:30 PM

$KAPA Anybody got any rocket emojis handy?

0 · Reply

Kairos Pharma Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 12 days ago

Kairos Pharma Proxy statement: Proxy filing

May 18, 2026, 4:00 PM EDT - 16 days ago

Kairos Pharma Transcript: 16th Annual LD Micro Invitational Conference

May 15, 2026, 7:00 AM EDT - 19 days ago

Kairos Pharma Slides: Investor presentation

May 14, 2026, 8:00 AM EDT - 20 days ago

Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award

May 13, 2026, 7:00 AM EDT - 21 days ago

Kairos Pharma Quarterly report: Q1 2026

May 13, 2026, 5:30 AM EDT - 21 days ago

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

May 11, 2026, 8:00 AM EDT - 23 days ago

Kairos Pharma Proxy statement: Proxy filing

May 8, 2026, 4:30 PM EDT - 26 days ago

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

Apr 15, 2026, 9:00 AM EDT - 7 weeks ago

Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Kairos Pharma Annual report: Q4 2025

2026-03-02T11:53:03.000Z - 3 months ago

Kairos Pharma to acquire CL-273 from Celyn Therapeutics

Mar 2, 2026, 6:30 AM EST - 3 months ago

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

2026-02-26T14:24:59.000Z - 3 months ago

Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn

Feb 26, 2026, 7:00 AM EST - 3 months ago

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Jan 20, 2026, 8:00 AM EST - 4 months ago

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Jan 13, 2026, 7:00 AM EST - 5 months ago

Kairos Pharma Registration statement: Registration Filing

2026-01-13T11:05:46.000Z - 5 months ago

Kairos Pharma files $75M mixed securities shelf

Dec 17, 2025, 8:15 AM EST - 6 months ago

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Nov 14, 2025, 7:00 AM EST - 7 months ago

Kairos Pharma Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 7 months ago

Kairos Pharma Provides Shareholder Update

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 5:00 PM EDT - 9 months ago

Kairos Pharma Transcript: Study Update

Sep 18, 2025, 5:00 PM EDT - 9 months ago

Kairos Pharma Press release: Study Update

2025-09-18T12:16:01.000Z - 9 months ago

Kairos Pharma announces interim efficacy analysis of ENV105

Sep 18, 2025, 8:00 AM EDT - 9 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 9 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Kairos Pharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:15 AM EDT - 9 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Kairos Pharma Quarterly report: Q2 2025

2025-08-04T14:05:21.000Z - 10 months ago

Kairos Pharma management to meet with Maxim

Jul 28, 2025, 12:28 PM EDT - 11 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 11 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

2025-07-16T01:26:00.000Z - 11 months ago

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

2025-07-15T13:15:24.000Z - 11 months ago

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Jul 15, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 16, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Registration statement: Registration Filing

2025-04-22T10:10:35.000Z - 1 year ago

Kairos Pharma files to sell 16.29M shares of common stock for holders

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 14, 2025, 6:00 PM EDT - 1 year ago

Kairos Pharma Annual report: Q4 2024

2025-04-03T10:16:23.000Z - 1 year ago

Kairos Pharma initiated with a Buy at H.C. Wainwright

2025-03-31T11:11:12.000Z - 1 year ago

Kairos Pharma completes safety lead-in of ENV105 trial

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

2025-03-27T11:40:11.000Z - 1 year ago

Kairos Pharma initiated with a Buy at Maxim

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

2025-02-26T12:27:01.000Z - 1 year ago

Kairos Pharma presents preclinical data on KROS 101, KROS 401

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

2025-02-18T13:42:31.000Z - 1 year ago

Kairos Pharma announces new DoD funding for ENV205 research

Feb 18, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

2025-02-11T13:36:20.000Z - 1 year ago

Kairos Pharma adds Huntsman Cancer Institute to Phase 2 ENV105 trial

Feb 11, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 29, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Registration statement: Registration Filing

Jan 28, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

2025-01-14T15:00:26.000Z - 1 year ago

Kairos Pharma Ltd trading resumes

Jan 13, 2025, 2:00 PM EST - 1 year ago

Kairos Pharma Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Earnings release: Q3 2024

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Kairos Pharma Transcript: 17th Annual LD Micro Main Event Conference

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 17, 2024, 1:00 PM EDT - 1 year ago

Kairos Pharma Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Aug 16, 2024, 8:00 AM EDT - 1 year ago

Kairos Pharma Registration statement: Registration Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing

May 13, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing

May 1, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oldshoe Jun. 1 at 4:57 PM

1 · Reply

TraderBuckNKY Jun. 1 at 3:45 PM

0 · Reply

TB85 May. 29 at 5:21 PM

1 · Reply

TraderBuckNKY May. 29 at 2:45 PM

$KAPA

0 · Reply

Oldshoe May. 27 at 4:30 PM

$KAPA

0 · Reply

Turkialharbi70 May. 26 at 1:14 PM

$KAPA

0 · Reply

uptrend2025 May. 22 at 2:19 PM

$KAPA Data and Partnership News next week?

0 · Reply

ezcheezie May. 21 at 8:25 PM

$KAPA Interesting my comment got deleted for some reason.

1 · Reply

uptrend2025 May. 21 at 8:02 PM

$KAPA 🚀 🚀

1 · Reply

Oldshoe May. 21 at 7:30 PM

$KAPA Anybody got any rocket emojis handy?

0 · Reply

ezcheezie May. 21 at 5:46 PM

$KAPA Slowly climbing back up, not much resistance. Very nice to see. Looks like solid support at .49. Need news and some volume and this will soar.

1 · Reply

KingJames_ May. 21 at 1:51 PM

$KAPA I love this company.... the amazing science and potential for a real breakout is all here.

0 · Reply

uptrend2025 May. 20 at 8:02 PM

$KAPA At least it closed above $0.50. Some progress.

1 · Reply

TB85 May. 20 at 2:52 PM

$KAPA Been away for a while, making money on other places, bringing profits back here. Yes, this is a true sleeper, but couldn't leave kapa forever, because the have a great thing going on. So, what are we waiting for near term, any kind soul in here could give a short update!??🙏 Thanks.

0 · Reply

Oldshoe May. 20 at 2:48 PM

$KAPA Watch for inflow at a 0.52 break

0 · Reply

Oldshoe May. 20 at 2:40 PM

$KAPA Need a 0.52 break for bullish momentum here

1 · Reply

Oldshoe May. 20 at 2:21 PM

$KAPA That 30k greèn candle at the 0.50 adds good color

1 · Reply

uptrend2025 May. 19 at 6:04 PM

$KAPA Don’t be a pooper close above $0.50 today por favor.

0 · Reply

uptrend2025 May. 19 at 4:26 PM

$KAPA When Partnership News? I want $2

1 · Reply

ezcheezie May. 19 at 2:20 PM

$KAPA Buy now

0 · Reply

Oldshoe May. 19 at 1:39 PM

$KAPA Buy now

0 · Reply

Xtracked May. 19 at 1:32 PM

$KAPA 1/2 million shares already. Ya.....It's coming

0 · Reply

Market Cap	10.91M
Revenue (ttm)	0.00
Net Income (ttm)	-5.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	217,117
Avg Vol	130,044
Day's Range	N/A - N/A
Shares Out	21.41M
Stochastic %K	3%
Beta	1.51
Analysts	Strong Sell
Price Target	$8.00